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Background: Differences in the expression of Natural Killer cell receptors have been reported to reflect divergent
clinical courses in patients with chronic infections or tumors. However, extensive molecular characterization at the
transcriptional level to support this view is lacking. The aim of this work was to characterize baseline differences in
purified NK cell transcriptional activity stratified by response to treatment with PEG-IFNα/RBV in patients chronically
infected with HCV.
Methods: To this end we here studied by flow cytometer and gene expression profile, phenotypic and transcriptional
characteristics of purified NK cells in patients chronically infected with HCV genotype-1 virus who were subsequently
treated with PEG-IFNα/RBV. Results were further correlated with divergent clinical response obtained after treatment.
Results: The pre-treatment transcriptional patterns of purified NK cells from patients subsequently undergoing a
sustained virologic response (SVR) clearly segregated from those of non-responder (NR) patients. A set of 476
transcripts, including molecules involved in RNA processing, ubiquitination pathways as well as HLA class II signalling
were differently expressed among divergent patients. In addition, treatment outcome was associated with differences
in surface expression of NKp30 and NKG2D. A complex relationship was observed that suggested for extensive
post-transcriptional editing. Only a small number of the NK cell transcripts identified were correlated with chronic
HCV infection/replication indicating that inherent transcriptional activity prevails over environment effects such as
viral infection.
Conclusions: Collectively, inherent/genetic modulation of NK cell transcription is involved in setting the path to
divergent treatment outcomes and could become useful to therapeutic advantage.
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Natural Killer (NK) cells were originally regarded as a
component of first-line innate immune defences against
invading pathogens and tumors [1]. This view has how-
ever considerably evolved to indicate that NK cells have
higher functional complexity in the regulation of other
innate and adaptive immune functions [2]. NK cell func-
tion relies on balanced signaling through inhibitory and* Correspondence: asciertoml@jhu.edu; de-maria@unige.it
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unless otherwise stated.activating receptors expressed on their surface [3,4] but
a high degree functional variability exists due to inter-
individual differences in inhibitory and activating recep-
tor expression, resulting in 30.000 up to >100.000 NK
cell phenotypes [5].
Triggering of activating NK cell receptor(s) and co-
receptors (Natural Cytotoxicity Receptors - NCRs,
NKp46, NKp44, NKp30; NKG2D; Fcγ-R; DNAM-1; NKC2C)
in the absence of overriding inhibitory signalling results in the
induction of NK cell function, including cytotoxicity and
cytokines production [6-10]. Differences in activating NK
cell receptor (i.e. NKp46, NKp30, DNAM-1, NKG2C)l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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function including cytotoxic activity [7], crosstalk with other
cells of the immune system [11-13], cytokines production in
recall-like responses [14-16], and control of pathogens repli-
cation through direct interaction with infected cells [17-22].
In line with these observations, in vivo differences in activat-
ing receptor density on peripheral NK cells are associated
with diverging clinical courses upon acute viral infec-
tion with hepatitis C virus (HCV) [19,21] and during
chronic HIV-1 infection [23-25]. During chronic HCV
infection, derangements in NK cell cytokines produc-
tion are detected involving interleukin 10 (IL-10) and
IFN-g production [26,27]. Interestingly, not only Killer-
Ig-like Inhibitory Receptors (KIR) germline carriage [28]
but also different expression of activating (i.e. NKp30,
NKp46) and inhibitory (i.e. CD85j) NK cell receptors [29]
are associated to diverging response.
There has been so far little scientific focus on the rela-
tionship between germline KIR carriage and actual KIR
transcription/expression or on the relationship between
activating receptor expression variability on the surface
of NK cells, and underlying differences in their transcrip-
tion. Thus, although converging evidences show that indi-
vidual differences in activating NK cell receptor expression
underlie diverging clinical courses, there has been so far no
molecular characterization at the transcriptional level to
support this view.
To address this issue, we studied phenotypic and tran-
scriptional characteristics of purified NK cells in patients
chronically infected with HCV genotype-1 virus who were
subsequently treated with PEG-IFNα/RBV showing diver-
gent clinical response to the treatment with either NR
or SVR. In the present work we show that in chronically
HCV-infected patients different baseline NK cell transcrip-
tional characteristics accompany and correspond to dif-
ferent surface marker phenotypes and diverging clinical
response to treatment.
Material and methods
Patients and blood samples
Training and validating set of HCV-1 patients
Nineteen patients chronically infected with HCV (HCV-1)
(n = 9 as part of the training cohort and n = 10 as part of
the validating cohort) followed up within program for
surveillance and treatment at the Hepatology Unite,
University of Genoa, Italy. Patients with HIV coinfection
or advanced liver involvement, including cirrhosis and
HCC were excluded. All patients gave full informed
consent to treatment and to observational sampling.
Patients were treated with pegylated IFN-a (180 g/ml)
and Ribavinin (600-1200 mg/day according to weight)
(PEG-IFNα/RBV, PR) and followed up for 48 weeks post
treatment according to Italian treatment guidelines. HCV
viral load was assessed at baseline and after 4 and 12 weeksof treatment to confirm early virus clearance. SVR was
defined as persistent HCV RNA negative by Amplicor
HCV Monitor (Roche, Milan, Italy) at end of treatment
and beyond 6 months after stopping treatment. Non-
responder patients (NR) included null-responders, partial
responders, and relapsers according to viremia kinetics
on treatment. HCV genotype was determined before
treatment in all patients with the INNO-LiPA HCV II
kit (Bayer Diagnostics, Emeryville, CA, USA). Only patients
with genotype I were evaluated. The samples were divided
in a training set and a validating set before analysis began.
Peripheral blood (20 ml) was collected before PEG-IFNα/
RBV treatment and used for PBMCs isolation by Ficoll
density gradient centrifugation. PBMCs were further used
for DNA and NK cells isolation as well as flow cytometer
analysis.Healthy donors and reverse validating group of patients
Peripheral blood (60 ml) derived from 7 healthy donors
(HD) and 8 chronically infected HCV patients used in the
reverse validation approach (CV-HCV) was collected at
the Department of Transfusion Medicine, Clinical Center,
National Institutes of Health with IRB approval. For CV-
HCV patients’ genotype assessment, INNO-LiPA HCV II
kit (Bayer Diagnostics, Emeryville, CA, USA) was used.
Only patients with genotype I were evaluated.
Pheripheral blood was used for PBMCs isolation by
Ficoll density gradient centrifugation.
PBMCs were further used for NK cells isolation as below
described. Detailed information about all patients used in
the study is reported in Table 1.DNA isolation and IL28 rs12979860 polymorphism
screening
DNA isolation from PBMCs derived from validating and
training groups of HCV patients was performed by using
Fujifilm’s Quickgene DNA Whole Blood kit (Fujifilm
Medical Systems USA, Stamford, CT). DNA was used for
screening of IL28B rs12979860 polymorphism by using
TaqMan® SNP Genotyping Assays (Life Technologies,
Grand Island, NY) following manufacturer’s instruc-
tions. Genetic correlation of IL28B rs12979860 CC
polymorphism with diverging clinical response was evalu-
ated by Fisher’s two tails exact test by using Graph Pad
Prism (San Diego, CA, USA).NK cells isolation from PBMCs
NK cells isolation from PBMCs was conducted via magnetic-
bead associated cell sorting, using Miltenyi’s Human
NK cell isolation (Miltenyi Biotec, San Diego, CA) kit for
negative selection.
Table 1 Patients information used in the whole study
Training group Validating group Healthy
donors
Reverse validating
group
Total
patients
HCV Treatment
Response
5 NR 4 SVR 5 NR 5 SVR NA NA n=19
Caucasian n=5 n=4 n=5 n=5 n=7 n=8 n=34
HCV genotype 1 n=5 n=4 n=5 n=5 NA n=8 n=28
HCV Treatment
naïve
n=5 n=4 n=5 n=5 n=7 n=8 n=34
Age mean±SD 44,2±18,36 32,3±14,43 60±7,8 51±6,4 45±4 48±16 n=34
Viral Load
mean ±SD
3256750 ±
2672345,209
646000 ±
234921,3
3076667 ±
2438080
1506000 ±
1887003
NA 1908796 ±
1457469
n=27
ALT mean±SD 90,25±41,83 48±7 66 ± 55 116±90,23 NA 72±65 n=27
F1 n=2 n=2 n=0 n=2 NA n=2 n=8
F2 n=0 n=1 n=0 n=1 NA n=2 n=4
F3 n=0 n=1 n=3 n=1 NA n=3 n=9
F4 n=3 n=0 n=2 n=1 NA n=3 n=9
Total patients n=9 n=10 n=7 n=8 n=34
Legend: NR = Non responders; SVR=sustained virologic responders; HD=Healthy donors. SD= Standard Deviation. Viral Load values are expressed as viral copies
(CP)/ml; ALT values are expressed as UI/ml. Fibrosis in patients with HCV was staged according to the Metavir classification, which ranges from F0 to F4 (F0 = no
fibrosis; F1 = portal fibrosis without septa; F2 = portal fibrosis with few septa; F3 = portal fibrosis with many septa; and F4 = cirrhosis).
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Following isolation, the purity of NK cells was evaluated
in all patients (SVR, NR, HD and CV-HCV) by immuno-
fluorescence analysis resulting in CD3−CD14−CD19−CD56+
gate >97%.
In training group of SVR and NR patients analysis of
NKp30 and NKG2D expression was evaluated by im-
munofluorescence on CD56 + CD3-CD14-CD19- PBMCs.
Because of increased number of isolated NK cells de-
rived from the 60 ml of peripheral blood, in CV-HCV
patients the expression of NKp30 and NKG2D expression
was evaluated by immunofluorescence directly on purified
NK cells. The correlation of NKp30 and NKG2D expression
with clinical response was performed by Mann–Whitney
u tests for unpaired datasets by using MedCalc Soft-
ware (Mariakerke, Belgium) and Stat graphics centurion
(Warrenton, VA, USA).
The following panel of mouse anti-human mAbs
was used for all immunofluorescence screenings: anti-
CD3, −CD19, −CD14 allophycocyanin (APC)-conjugated
(BD PharMingen, San Jose, CA, USA), anti-CD56 PeC7-
conjugated (Immunotech-Coulter Marseille, France). Anti-
NKp30 and NKG2D were in house produced and gently
provided by A. Moretta. Briefly, cells were incubated
with primary mAbs followed by PE- or FITC-conjugated
anti-isotype-specific goat anti-mouse secondary reagents
(BD PharMingen, San Jose, CA, USA). Direct staining was
performed by fluorochrome-conjugated mAbs as a third
step. For cytofluorimetric analysis, cells were gated using
forward and side light scatter parameters (FACSCantoII,
BD, Mountain View, CA, USA) and 10,000 events werealways acquired. Data were analysed using FlowJo (Tree
Star, Inc.).
Gene expression array
Total RNA was purified from NK cells derived from HD,
SVR, NR and CV-HCV individuals by using miRNeasy
minikit (Qiagen, Germantown, MD,USA) according to
the manufacture’s protocol. RNA quality and quantity was
estimated using Nanodrop (Thermo Scientific, Waltham,
MA, USA) and Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA, USA). First- and second-
strands cDNA were synthesized from 30 ng of total RNA
by using Nugen Ovation Pico WTA System V2 (Nugen
technologies, San Carlos, CA, USA) and following manu-
facturer’s instructions. cDNAs were fragmented and bio-
tinylated by using Nugen Encore Biotin Module (Nugen
technologies, San Carlos, CA, USA) and hybridized to the
GeneChip Human Gene 1.0 ST Arrays (Affymetrix, Santa
Clara, CA, USA). The arrays were washed and stained
on a GeneChip Fluidics Station 450 and scanned by
GeneChip Scanner 3000 (Affymetrix, Santa Clara,CA,
USA). The global gene expression profiling of NK cells
was analyzed using BRBArrayTools developed by the Bio-
metric Research Branch, NCI (http://linus.nci.nih.gov/
BRB-ArrayTools.html) and Partek Genomics Suite (St
Louis, MO). Functional analysis was performed using
the Ingenuity Pathway Analysis system (IPA), a web-based
software application for the analysis, integration, and in-
terpretation of data derived from ‘omics’ experiments,
such as RNAseq and microarrays. Powerful algorithms
identified regulators, relationships, mechanisms, functions,
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Results
Molecular organization of NK cells during HCV infection is
associated with treatment outcome
Purified NK cells from prospectively collected cryopre-
served PBMCs on a set of 9 sequential HCV patients
starting treatment with PEG-IFNα/RBV for 48 weeks
were evaluated first.
Gene expression arrays were employed for global tran-
scriptional profiling of the purified NK cells and stratified
for comparison according to treatment outcome (5
non-responder (NR) and 4 sustained virological responder
(SVR)). Purified peripheral NK cells from 7 healthy donors
(HD) were used as control.
Principal Component Analysis (PCA), a method that
identifies gene-expression patterns (principal components)
that best explain variance across a data set, was performed
on the whole dataset (33,304 transcripts) revealing that
pre-treatment transcriptional patterns of purified NK cells
were clearly heterogeneous. In particular, transcriptional
profiles from patients with subsequent SVR on treatment
clearly segregated apart from those of NR patients. Sur-
prisingly, despite the presence of chronic HCV replication,
a similar NK transcriptional pattern was found for SVR
and HD (Figure 1A).
Prior to treatment our analysis identified 476 transcripts
differentially expressed by NK cells in patients withFigure 1 Trascriptional profile of NK cells derived from HCV infected pa
on whole gene dataset expressed by NK cells of Healthy Individuals (HD)
B) Supervised cluster based on 476 genes derived from Student’s t Test (SVR compared to NR (cut off p2 value ≤ 0.005; Fold
Change >1.5). Among differentially expressed transcripts,
416 were up-regulated (Additional file 1: Table S1) and
60 were down-regulated (Additional file 2: Table S2) in
patients who subsequently responded to treatment.
A supervised clustering was performed using these 476
transcripts in SVR and NR patients. In order to evaluate
the trend of expression of the 476 differentiating genes
also in healthy donors, the supervised clustering was
conducted also by including the value of expression of
the 476 genes in healthy individuals. The results dem-
onstrated that the expression of genes differentially
expressed in SVR vs NR patients are instead similarly
expressed in SVR vs. HD.
Functional analysis performed by Ingenuity Pathways
Analysis (IPA) of the 476 NK genes showed that the tran-
scripts which correlated most significantly with treatment
outcome were those coding for molecules involved in
post-transcriptional modification of RNA/protein traffick-
ing and those associated with HLA class II signaling
(Figure 2A). In particular, purified NK cells from SVR
patients displayed an increased expression of genes involv-
ing post transcriptional regulation and alternative spli-
cing such as small nucleolar RNAs (snoRNA, known
also as SNORD). Indeed, the top down-regulated tran-
scripts in NR patients were snoRNAs. Although the
exact mechanism of action of snoRNA is still undefined,
snoRNAs have been shown to orchestrate the splicing of
RNA [30,31] and the folding of pre-rRNA necessary fortients with diverging treatment response. A) PCA analysis conducted
, baseline responders (SVR) and non-responders (NR) HCV-1 patients.
cut off p2 value ≤ 0.005, FC >1.5) SVR vs. NR.
Figure 2 Functional analysis conducted on genes differentially expressed in HCV patients with diverging treatment response. A) IPA
analysis conducted on the 476 transcripts differentially expressed in SVR vs. NR patients showed in the top network that molecules involved in
mRNA processing and protein synthesis (such as SRSF molecules) are up regulated (in red) in SVR samples. B) Top 5 significant ranking significant
(threshold p value < 0.05) canonical pathways conducted on the 476 transcripts reveled an up regulation of ubiquitination pathways as well as
tRNA charging pathways in SVR patients. On the contrary, molecules involved in antigen presentation pathways are showed to be down regulated in
SVR patients. The p value for each pathway is indicated by the blue bar and is expressed as –1 times the log of the p value. The yellow line
represents the ratio of the number of genes in a given pathway that meet the cutoff criteria divided by the total number of genes that make
up that pathway.
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the nucleolus [32]. In addition to snoRNAs, other
molecules involved in RNA processing such as serine/
arginine-rich splicing factors (SRSF) also were found over-
expressed in SVR. The findings were confirmed by func-
tional analysis conducted on the 476 genes by using IPA.
In particular the results revealed an up regulation of
molecules involved in mRNA processing and protein
translation functions in SVR patients (Figure 2A). Simi-
lar results were obtained by looking at first significant
(p value < 0.05) canonical pathways in which molecules
involved in ubiquitination pathways and RNA charging path-
ways are shown up regulated in SVR patients (Figure 2B).
These observations further support the presence of relevant
differences in the arrangement of RNA processing and
protein synthesis machinery of NK cells in differentpatient groups and different treatment outcomes. No over-
all difference was observed in the interferon-stimulated
transcript pathway.
Protein expression of NKp30 and NKG2D correlates with
divergent treatment responses during HCV infection
We next examined possible differences in surface molecule
expression/phenotype by flow cytometry to further evalu-
ate their transcriptional correlates (Figure 3A). Flow cytro-
metric analysis of PBMCs in the training group of patients
showed that SVR patients had decreased proportions of
CD56 + NKp30+ (Mann–Whitney U-test p = 0.04) and
of CD56 + NKG2D+ (Mann–Whitney U-test p = 0.01)
(Figure 3B). No differences were observed for other NCRs
(data not shown). These results were in line with previous
work showing that NKp30 is differentially expressed on
Figure 3 Correlation of activating NK cell receptor (NKp30 and NKG2D) expression with divergent treatment responses during HCV
infection. A) Representation of gating strategy adopted for the evaluation of NKp30 and NKG2D expression in the CD56 + CD3-CD19-CD14- PBMCs
derived from training SVR and NR patients. B) Further correlation (Mann Whitney u test) with INFα + rivabirin treatment response showed a significant
up regulation of NKp30 and NKG2D in NR. Results obtained for NKp30 confirmed previous observations [29].
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ribavirin treatment vs. non-responder patients [29].
Despite their low surface expression, the molecular
expression of NKp30 was not significantly different in
SVR vs. NR patients (p = 0.88, Student’s t test). Indeed,
the NKG2D transcript was found to be up-regulated in
patients with SVR (p value 0.003). The decreased protein
surface expression of NKG2D with increased transcript
presence at baseline in SVR patients suggested a “protective”
role played by posttranscriptional events. This is in line
with other reports and confirms that the surface molecule
expression of NKG2D is regulated by extensive posttran-
scriptional mechanism(s) [33].Validation of the SVR: NR gene set transcriptional profile
in independent cohorts of HCV patients
The significant individual differences observed in the tran-
scriptional activity of purified NK cells in HCV-patients
after patient stratification according to response to treat-
ment raised the question of whether this was the result of
a selection bias in patients entering in a single treatment
trial.We therefore studied whether the 476 gene-signature
set identified in NK cells from NR vs. SVR patients
would also segregate in chronically infected patients
followed independently in another cohort of patients.
To this end, independent gene expression analysis was
performed on purified NK cells from PBMCs derived
from 5 NR and 5 SVR patients from University of Genoa,
Italy. Samples were obtained prior to treatment with
PEG-IFN/RBV. PCA analysis was performed on this
validating group of patients by using the 476 transcripts
identified in the training set of patients, and confirmed
that this gene set could efficiently differentiate SVR from
NR patients in an independent cohort (Figure 4A).
Next, we studied a new group of 8 treatment-naive
chronically infected HCV-patients (CV-HCV) followed up
in a natural history study in North America (Clinical
Center, NIH, MD, USA). Gene expression profiling was
performed on their purified NK cells derived from PBMCs.
PCA analysis performed on the 476-transcript signature
showed segregation of these patients into two groups. In
particular, PCA analysis showed that one group of patients
(n = 4) had transcript signatures very similar to that ob-
tained in healthy donors and in patients that had sustained
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Figure 4 The SVR: NR gene set transcriptional profile is validated in independent cohorts of HCV patients. A) PCA analysis performed on
the independent group of patients by using the 476 genes associated with treatment response in the training set of patients; B) PCA analysis performed
on 8 treatment naïve chronically infected HCV patients (CH-HCV) by using the 476-transcript signature segregated the CH-HCV patients according
a SVR-like and NR-like. Because of the high heterogeneity of NK profile derived from NR-like patients, the PCA was conducted by adding a
centroid for each group of patients. C) The expression of NKp30 and NKG2D was evaluated on purified NK cells showing to be higher in NR-like
patients as previously reported to occur for NR patients [29,34].
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Figure 1A. The remaining patient group (n = 4) was
clearly different from HD and those with SVR and was
highly heterogeneous. We hypothesized that this group
would behave as NR or as relapsers when treated with a
standard PR treatment regimen (Figure 4B). To verify
this assumption we reverse validated data (thus reverse
validating approach) by studying the expression of
NKG2D and NKp30 on their peripheral NK cells after
gene signature stratification. In the reverse validating
approach, cytofluorimetric analysis of CD3−CD56+NKp30+
and CD3−CD56+NKG2D+ showed a significantly lower
expression of NKp30 and NKG2D in patients with an
NK cell transcriptional profile very comparable to HD
(SVR-like group) and conversely an increased expression
in NR-like group (Figure 4C). This finding thus indicates
that the identified transcriptional NK cell pattern in
treated patients is also reflected in a different group oftreatment-naive patients and differentiates those with
enhanced potential for SVR [35] from those who would
not respond to peg-IFNα + ribavirin treatment. Taken
together, these observations show that in any given
setting at least two gene signatures may be identified in
HCV patients independent of the clinical setting and
location.
Inherent HCV-independent transcriptional regulation of
NK cells underlies divergent clinical responses to treatment
with IFN-a and ribavirin
The level of HCV replication prior to treatment is likely
to affect baseline NK cell transcriptional activity and
function. To determine the extent of this interaction,
we next studied whether the differential expression of
the 476 NK transcripts could be affected by HCV
viremia. To this end, we compared the transcriptional
profiles of purified peripheral NK cells from healthy
Ascierto et al. Journal of Translational Medicine  (2015) 13:77 Page 8 of 11donors (HD) and from chronically viremic HCV-infected
patients (CH-HCV). Comparative analysis identified 165
transcripts differentially expressed by NK cells in HD
vs. CH-HCV (Student’s T test p2 v ≤ 0.005, FC ≥1.5)
(Figure 5A). Among the most up-regulated transcripts
in CH-HCV patients, were molecules involved in inter-
feron signaling (Additional file 3: Table S3), whose expres-
sion has been previously reported to be increased in the
course of HCV infection in these patients [36]. A Venn
diagram showed that among the 165 transcripts, only 22
transcripts (5%) were included in the set of 476 transcripts
previously found to differentiate SVR from NR patients
(Figure 5B). Conversely, 95% of the genes whose transcrip-
tion is affected by HCV were not included in the list of
those that are differentially expressed among patients ac-
cording to their response to treatment.
These results thus show that only a negligible fraction
of the NK cells transcripts that are modulated by
chronic HCV replication are able to clinically segre-
gate NR from SVR patients. Rather, inherent HCV-
independent transcriptional regulation of NK cells
underlies divergent clinical responses to treatment
with IFN-a and ribavirin.
IL28B rs12979860 polimorphism doesn’t clearly distinguish
patients with widely diverging outcome in our series of
patients
Genetic polymorphisms near the IL28B gene, encoding
interferon-λ-3 (IFN-λ-3), gene have been previously as-
sociated with response to treatment [37].Figure 5 Analysis of pre-treatment NK cells trascriptome according to
derived from Student’s t Test Chronic Viraemic HCV patients (CV-HCV) vs. H
genes able to differentiate NR vs. SVR patients and the 165 genes associate
NR, only 22 genes (5%) were affected by viremia.In order to investigate this aspect in our dataset, IL28B
rs12979860 polymorphism screening was performed by
RT-PCR using DNA extracted from PBMCs of both
the training and validating groups of HCV-1 patients.
These results showed that IL28B IL28B rs12979860
polymorphism was not significantly associated with SVR
in our series of patients (F test p =0.99) (Additional file 4:
Table S4).
Discussion
In the present work we studied peripheral NK cell tran-
scriptional diversity in patients chronically infected with
HCV by microarray analysis and flow cytometry showing
that inter-individual NK cells baseline differences exist
and may predict subsequent diverging responses to treat-
ment in interferon-based regimens. Relevant inter-individual
differences in mature peripheral NK cell phenotype have
been described previously in patients with chronic in-
fections and divergent clinical courses or treatment re-
sponses [24,28,29]. In these instances, NK cell receptors
are poorly expressed but are inducible in patients control-
ling HIV infection spontaneously (NKp30, NKp46) and in
those clearing HCV upon peg-IFNa/ribavirin treatment
(NKp30). Although differences in individual surface
expression are the consequence of individual nuances
in transcriptional regulation of cell transcription, thus
far these have received little attention. The present
characterization represents, to our knowledge, the first
attempt to shed light on this aspect during chronic
HCV infection. In this study, PCA analysis identifiedthe level of HCV viremia. A) Supervised cluster based on 165 genes
D (Cut off p value <0.005; FC > 1.5). B) Venn diagram between the 476
d with viremia. Among the genes able to segregate the SVR from the
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cording to subsequent treatment response to IFN (SVR
vs. NR). This observation is in line with transcriptional
differences in NK-cell specific genes observed in patients
with recurrent vs. nonrecurring breast cancer [38,39] and
in GIST (Gastrointestinal Chronic Tumor) [40], where
NK cell signatures of activating receptor transcription
in tumor infiltrating lymphocytes are associated with non-
recurring disease. Previous work showed that in patients
who will respond to IFN treatment, NKp30 expression
on peripheral NK cells is significantly lower compared
to non-responding patients. Here we confirmed this
observation and extended it also to NKG2D expression.
Surprisingly, the differences in transcriptional activity
of peripheral NK cells among SVR and NR patients did
not directly support some of the phenotypic differences
observed (such as the decreased surface expression of
NKp30 and NKG2D). These findings suggest that differ-
ences in the expression of NK cells derived from patients
with different treatment outcomes might be affected by
extensive posttranscriptional regulation. Indeed, there
was a significant upregulation of SNORDs and regulatory
small RNAs in SVR patients, raising the possibility of rele-
vant posttranscriptional regulation in SVR, but not in
NR where small noncoding RNAs (ncRNAs) expression
is lower. These data indicate that the relevance of the
non-coding genome is not limited to microRNA (miRNA)
expression and function, and that other ncRNAs, (i.e.:
snoRNAs) are involved in the shaping of inherently differ-
ent NK immune responses resulting in a different arrange-
ment of the protein synthesis machinery. Whether this
observation may be exploited for clinical predictive evalu-
ation of response to treatment, or for other clinical
purposes in view of the advent of new HCV-specific
regimens, is still undefined. Large quantification and
clinical validation studies would be needed to confirm
this possibility. Along this line, the finding that HD
tightly clustered with SVR based on the expression of
genes differentially expressed between SVR vs NR may
be surprising. Indeed considering the 40-60% chance
of chronically infected patients of responding to PR
treatment, and given the 30% probability of any acutely
infected patient to spontaneously clear the infection, it
can be expected that HD are particularly enriched in
subjects either spontaneously clearing the infection
(30%) or responding to treatment (50% of 70% i.e. 35%).
This could mean that up to 70% of any HD cohort could
share the SVR signature. Therefore, the observed HD-SVR
clustering may be explained by the small sample size, and
needs to be addressed further in larger HD cohorts. In
addition to the down-regulation of molecules involved in
post transcriptional events we observed a very significant
up-regulation of HLA class II transcripts in NK cells from
NR patients. This is in line with the crucial role played byHLA class II molecules in treatment-induced-clearance
of HCV and is supported by previous reports showing
that SNPs marking HLA-class II (i.e. Homozygous C1
supertype) are strongly associated with the outcome of
Hepatitis C Virus Infection [41,42]. Moreover, the present
results additionally suggest that not only qualitative (i.e.
homozygous C1 supertype) but also quantitative (i.e. in-
creased HLA class II transcription) differences in NK
cell HLA are relevant and may efficiently discriminate
patients with diverging treatment responses and disease
courses.
Surprisingly, none of the genes found to differentiate
patients with diverging clinical response to therapy were
related to the IL28B polymorphism, nor an IL28B CC
homozygosis was significantly associated with SVR in
our series of patients. These results should however be
considered in the perspective of an analysis deriving from
a small cohort of patients as opposed to large population
statistics needed for correct SNPs evaluation.
Comparison of microarray transcriptional regulation in
all HCV patients to a group of healthy donors allowed in-
vestigation of the extent to which differences in NK cell
transcriptional regulation reflect the effects of chronic
HCV infection per se. Indeed, HCV replication affects per-
ipheral NK cell transcriptional activity, as shown by the
presence of 165 differentially regulated genes. Notably,
only 22 of these 165 transcripts were included in the set of
476 genes that allowed differentiation between treatment
responders and non-responders. Therefore, the transcrip-
tional (and phenotypic) differences observed here in SVR
vs. NR patients reflect a predominantly (95%) inherent
regulation of treatment response in HCV-infected patients,
with only a minor influence of HCV replication.
In the present analysis we identified at least two
inherent/genetic NK cell signatures when analyzed by
PCA analysis and stratified by clinical response to treat-
ment. This analysis, however, does not exclude that strati-
fication by other parameters might provide additional
insights into NK activity. In contrast to mass cytometry,
one of the limits of the present microarray analysis and
standard flow cytometry is the need to consider mean
values in a group disregarding the many nuances of NK cell
molecule transcription/expression. For example, additional
transcriptional groupings may be observed when analyses
are performed on different NK cell subsets (i.e. CD56bright,
CD56dim, CD56-) or on NK cells expressing NKG2C, or
residing in the liver during chronic HCV infection.
Conclusions
This work provided a transcriptional context for known
and previously unknown molecular aspects of NK cell
identity and function. By delineating the genome-wide rep-
ertoire of gene expression of NK cells in HCV patients and
using diverging response to treatment regimens as
Ascierto et al. Journal of Translational Medicine  (2015) 13:77 Page 10 of 11dissecting tool, we confirm that different gene signatures
underlie previously described phenotypic differences. A
multiplicity of transcriptional regulators is involved in this
diversity of innate NK cell responses with inherent genetic
determinants predominating over environmental (i.e. HCV)
factors.
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